William Pickering
Stock Analyst at Bernstein
(1.75)
# 3,358
Out of 5,157 analysts
33
Total ratings
47.62%
Success rate
-1.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $90 → $94 | $60.88 | +54.40% | 6 | Feb 25, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $37 → $41 | $27.62 | +48.44% | 2 | Jan 21, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | n/a | $460.87 | - | 6 | Jan 12, 2026 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $94 | $65.64 | +43.21% | 1 | Dec 11, 2025 | |
| BHVN Biohaven | Downgrades: Market Perform | $34 → $9 | $10.21 | -11.85% | 3 | Nov 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $155 → $157 | $188.24 | -16.60% | 1 | Nov 3, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Market Perform | $14 → $15 | $13.89 | +4.39% | 2 | Oct 28, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $753 → $781 | $781.60 | -0.08% | 3 | Aug 27, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Market Perform | $13 | $17.64 | -26.30% | 1 | Jul 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $314 → $310 | $323.59 | -4.20% | 2 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $27 → $24 | $60.67 | -60.44% | 2 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $75.36 | - | 2 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $6 | $2.50 | +140.00% | 1 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $44 | $58.78 | -25.14% | 1 | Mar 21, 2023 |
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $94
Current: $60.88
Upside: +54.40%
Beam Therapeutics
Jan 21, 2026
Maintains: Outperform
Price Target: $37 → $41
Current: $27.62
Upside: +48.44%
Vertex Pharmaceuticals
Jan 12, 2026
Upgrades: Outperform
Price Target: n/a
Current: $460.87
Upside: -
BridgeBio Pharma
Dec 11, 2025
Initiates: Outperform
Price Target: $94
Current: $65.64
Upside: +43.21%
Biohaven
Nov 6, 2025
Downgrades: Market Perform
Price Target: $34 → $9
Current: $10.21
Upside: -11.85%
Biogen
Nov 3, 2025
Maintains: Market Perform
Price Target: $155 → $157
Current: $188.24
Upside: -16.60%
Intellia Therapeutics
Oct 28, 2025
Downgrades: Market Perform
Price Target: $14 → $15
Current: $13.89
Upside: +4.39%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Outperform
Price Target: $753 → $781
Current: $781.60
Upside: -0.08%
Sarepta Therapeutics
Jul 29, 2025
Initiates: Market Perform
Price Target: $13
Current: $17.64
Upside: -26.30%
Alnylam Pharmaceuticals
Jan 7, 2025
Maintains: Outperform
Price Target: $314 → $310
Current: $323.59
Upside: -4.20%
Nov 29, 2024
Maintains: Market Perform
Price Target: $27 → $24
Current: $60.67
Upside: -60.44%
Jun 14, 2024
Upgrades: Market Perform
Price Target: n/a
Current: $75.36
Upside: -
Mar 21, 2023
Initiates: Market Perform
Price Target: $6
Current: $2.50
Upside: +140.00%
Mar 21, 2023
Initiates: Market Perform
Price Target: $44
Current: $58.78
Upside: -25.14%